Thaisrivongs S, Turner S R, Strohbach J W, TenBrink R E, Tarpley W G, McQuade T J, Heinrikson R L, Tomasselli A G, Hui J O, Howe W J
Department of Medicinal Chemistry, Upjohn Laboratories, Upjohn Company, Kalamazoo, Michigan 49001.
J Med Chem. 1993 Apr 16;36(8):941-52. doi: 10.1021/jm00060a001.
A number of potential HIV protease inhibitory peptides that contain the dihydroxyethylene isostere were prepared and evaluated for their enzyme binding affinity and antiviral activity in cell cultures. From the template of a previously reported active peptide A, modifications at the N- and C-terminal groups were assessed for potential maintenance of good inhibitory activity of the resulting peptides. Among the active peptides found, peptide XVIII exhibited potent enzyme inhibitory activity. Interestingly, the previously reported, effective 1(S)-amino-2(R)-hydroxyindan C-terminal group for the preparation of very active HIV protease inhibitory peptides could not be applied to the template of peptide XVIII. Molecular modeling of peptide XVIII was studied using the X-ray crystal structure of peptide A as a starting point in order to study the likely conformation of peptide XVIII in the active-site cleft. Relative binding conformations of peptide A and XVIII were obtained, although the reason for poor binding affinity for a number of congeneric peptides in this report was not straightforwardly apparent. More importantly, however, peptide XVIII was found to exhibit more effective antiviral activity in the HIV-1/PBMC assay than the reference peptide A which was previously reported to be approximately equal in efficacy to the reverse transcriptase inhibitor AZT in this assay.
制备了多种含有二羟基乙烯电子等排体的潜在HIV蛋白酶抑制肽,并在细胞培养中评估了它们的酶结合亲和力和抗病毒活性。以先前报道的活性肽A为模板,评估了N端和C端基团的修饰对所得肽良好抑制活性的潜在维持作用。在发现的活性肽中,肽XVIII表现出强大的酶抑制活性。有趣的是,先前报道的用于制备高活性HIV蛋白酶抑制肽的有效的1(S)-氨基-2(R)-羟基茚C端基团不能应用于肽XVIII的模板。以肽A的X射线晶体结构为起点,研究了肽XVIII的分子模型,以研究肽XVIII在活性位点裂隙中的可能构象。获得了肽A和XVIII的相对结合构象,尽管本报告中许多同类肽结合亲和力差的原因并不直接明显。然而,更重要的是,发现在HIV-1/PBMC试验中,肽XVIII比参考肽A表现出更有效的抗病毒活性,先前报道在该试验中参考肽A的疗效与逆转录酶抑制剂AZT大致相当。